Eptifibatide
Also known as: Integrilin, Barbourin analog
A cyclic heptapeptide platelet GP IIb/IIIa inhibitor given IV in acute coronary syndromes and PCI. FDA-approved as Integrilin (1998). Hospital medication.
Last updated
Mechanism of Action
Eptifibatide is a cyclic heptapeptide modeled on barbourin, a protein in the venom of the southeastern pygmy rattlesnake. It reversibly blocks the platelet glycoprotein IIb/IIIa receptor, preventing fibrinogen and von Willebrand factor from bridging platelets, which is the final common step of platelet aggregation. Platelet function returns within hours of stopping the infusion, and the drug is cleared largely by the kidneys.
- Half-life
- ~2.5 hours (IV)
- Administration Routes
- Intravenous
- Research Status
- Clinical
Reported Benefits
- Reduces death or heart attack in acute coronary syndromes (PURSUIT)
- Reduces ischemic complications during PCI with stenting (ESPRIT)
- Rapid onset and offset of platelet inhibition
Potential Side Effects
- Bleeding, including major bleeding
- Thrombocytopenia
- Hypotension
Common Dosing
Eptifibatide is given only in hospital as an intravenous bolus followed by a continuous infusion, alongside aspirin and an anticoagulant. Doses are weight-based, the infusion is reduced for kidney impairment, and it is avoided in patients on dialysis. Dosing is set and supervised by the prescribing clinician.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active or recent abnormal bleeding, or hemorrhagic stroke history
- Severe uncontrolled hypertension
- Recent major surgery or stroke
- Dependency on kidney dialysis
No documented stacking partners for Eptifibatide yet.